Mydecine Innovations Group, Inc. is a biotechnology company. It engages in the business of creating the latest novel drugs and therapies to treat mental health conditions like nicotine addiction and post-traumatic stress disorder. The company was founded by Parente Carman, Damon Michaels, and Robert Roscow on September 27, 2013 and is headquartered in Vancouver, Canada.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company